Inhibrx Inc
INBX · NASDAQ
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi.
ESG Scores
Overall ESG5.7
Environmental5.4
Social4.0
Governance5.9
Gender Diversity
Female Directors0.4%
Female Executives0.2542372881355932%
CEO GenderMale
Market Data
Price$82.39-5.85 (-6.62%)
Market Cap$1.29B
P/E Ratio—
EPS$—
52W High$94.57
52W Low$10.84
Beta2.57